Feeds

Final drug trial victim out of the woods

As placebo man balks at follow-ups

Seven Steps to Software Security

All of the volunteers given an experimental immune drug in a London trial have now made it off the critical list at Northwick Park hospital.

The last of six men given biotech firm TeGenero's TGN1412 compound is now fully conscious and looks set to make a full recovery.

Intensive care clinical director Dr Ganesh Suntharalingam said: "We are delighted that the six patients have come through safely from the most critical stage of their condition."

He praised intensive care staff for how they dealt with the victims' very serious condition when they were transferred there from a private testing unit more than three weeks ago.

TeGenero said today its preliminary investigations showed it had followed all correct procedures in the animal testing phase of the drug. It also says the problem was unforseeable based on preclinical results (see here for why many think the problems might have been foreseeable though).

Watchdog the Medicines and Healthcare products Regulatory Agency (MHRA) agreed, saying it hasn't been able find a problem with how the trial was carried out.

It also couldn't find evidence of contamination of the drug. Some had speculated bacterial toxins might be responsible for the multiple organ failure.

MRHA added that its findings are not yet conclusive, but that the suspected flaws in the action of the drug itself were the most likely cause. The Secretary of State for Health is assembling a panel of experts to investigate why the animal trials didn't pick up the near-deadly complications.

Meanwhile, Raste Khan, 23, one of the men given a harmless placebo, appeared in The Sun today, saying he was still traumatised by what he saw during the trials. "I still feel haunted by it and I know my family have been extremely upset. I am too frightened even to get sleeping pills from the doctor."

He claims test contractor Parexel is demanding he honour the terms of his contract by attending follow-ups in order to pocket his £2,000 volunteer fee.

Testing contractor Parexel was unavailable for comment. ®

The Power of One eBook: Top reasons to choose HP BladeSystem

More from The Register

next story
Beancounters tell NASA it's too poor to fly planned mega-rocket
Space Launch System would need another $400m and a lot of time
Malaysian Airlines flight MH17 claimed lives of HIV/AIDS cure scientists
Researchers, advocates, health workers among those on shot-down plane
Bad back? Show some spine and stop popping paracetamol
Study finds common pain-killer doesn't reduce pain or shorten recovery
World Solar Challenge contender claims new speed record
One charge sees Sunswift travel 500kms at over 100 km/h
Vote now for LOHAN's stirring mission patch motto
Does the shed actually know no bounds, or what?
SMELL YOU LATER, LOSERS – Dumbo tells rats, dogs... humans
Junk in the trunk? That's what people have
All those new '5G standards'? Here's the science they rely on
Radio professor tells us how wireless will get faster in the real world
The Sun took a day off last week and made NO sunspots
Someone needs to get that lazy star cooking again before things get cold around here
prev story

Whitepapers

Top three mobile application threats
Prevent sensitive data leakage over insecure channels or stolen mobile devices.
Implementing global e-invoicing with guaranteed legal certainty
Explaining the role local tax compliance plays in successful supply chain management and e-business and how leading global brands are addressing this.
Top 8 considerations to enable and simplify mobility
In this whitepaper learn how to successfully add mobile capabilities simply and cost effectively.
Application security programs and practises
Follow a few strategies and your organization can gain the full benefits of open source and the cloud without compromising the security of your applications.
The Essential Guide to IT Transformation
ServiceNow discusses three IT transformations that can help CIO's automate IT services to transform IT and the enterprise.